Non‐fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX
- 23 June 2004
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 2 (7) , 1104-1109
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Markers of endothelial damage in organ dysfunction and sepsisCritical Care Medicine, 2002
- Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic RangeChest, 2001
- Hemorrhagic Complications of Anticoagulant TreatmentChest, 2001
- ART‐123: Recombinant Human Soluble ThrombomodulinCardiovascular Drug Reviews, 2000
- Incidence of Recurrent Thromboembolic and Bleeding Complications Among Patients With Venous Thromboembolism in Relation to Both Malignancy and Achieved International Normalized Ratio: A Retrospective AnalysisJournal of Clinical Oncology, 2000
- High Concentration of Thrombomodulin in Plasma Is Associated With HemorrhageCirculation, 1997
- A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism.Journal of Clinical Investigation, 1996
- Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)The Lancet, 1996
- Bleeding Complications in Oral Anticoagulant TherapyArchives of internal medicine (1960), 1993
- Complete nucleotide sequences of the gene for human factor IX (antihemophilic factor B)Biochemistry, 1985